RxDoctor Payments Data

Jenna Davis

Nurse Practitioner · Columbia, SCNPI 1871217935

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,843 and has fallen 89.9% since, to $185 in 2025.

$2,739in general payments, 2019–2025

Across 133 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$270
  • AstraZeneca$223
  • Lilly USA, LLC$210
  • Johnson & Johnson$167
  • Merck$166
  • Novo Nordisk$137
  • plus $2K from 39 others
$198,926in research payments, 2019–2025

Across 1 payment — averaging $198,926 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Servier Bioinnovation$199K

What the payments were for

  • Food & beverage$2,739100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,739 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$41,360
Medicare patients
155
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$31,922
MounjaroTirzepatide12$16,502
EliquisApixaban12$11,455
Rosuvastatin Calcium29$854
Atorvastatin Calcium52$615
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide12$474
Pantoprazole Sodium30$454
Fluticasone Propionate43$372
Albuterol Sulfate HfaAlbuterol Sulfate15$340
Pravastatin Sodium18$335
Amlodipine Besylate67$334
Carvedilol17$277
Donepezil Hcl14$230
Diclofenac Sodium17$193
Losartan Potassium26$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$137$31,92223 claims
Lilly USA, LLCMounjaro$210$16,50212 claims
PfizerEliquis$13$11,45512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →